Dexamethasone Irrigation of the Parotid Glands in Primary Sj(SqrRoot)(Delta)Gren s Syndrome Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01316770|
Recruitment Status : Completed
First Posted : March 16, 2011
Last Update Posted : October 19, 2017
- Sj(SqrRoot)(Delta)gren s syndrome is an autoimmune disease (where the immune system attacks normal body tissues) that affects the salivary glands. Many people with Sj(SqrRoot)(Delta)gren s syndrome are not able to make enough saliva because their salivary glands are inflamed. The dry mouth that results can interfere with daily activities and can lead to dental cavities, mouth sores, and infections. Injections of corticosteroids into the parotid glands can improve saliva production in people with to Sj(SqrRoot)(Delta)gren s syndrome, but current treatment practices may provide only temporary relief. Researchers are interested in studying the effectiveness of stronger corticosteroid injections (using dexamethasone) to determine how the corticosteroid treatment actually works.
- To evaluate the effectiveness and mechanics of dexamethasone injections to improve saliva production in individuals with primary Sj(SqrRoot)(Delta)gren s syndrome.
- Women between 18 and greater of age who have been diagnosed with primary Sj(SqrRoot)(Delta)gren s syndrome, and have had a biopsy of the minor salivary glands in the past 5 years that shows a moderate level of inflammation.
- Participants will be screened with a full medical history and physical examination, blood and urine tests, and salivary gland biopsies. Participants will also be screened with tests of saliva flow production and evaluation of the salivary ducts and glands, and will complete questionnaires about dry mouth symptoms.
- At the first treatment visit, participants will receive an injection of dexamethasone into one parotid gland and an injection of saline into the other gland. After the injections, participants will provide a blood sample to test the level of dexamethasone in the blood.
- Two weeks after the first treatment, participants will return for an evaluation visit to have saliva flow rate measurements taken, and will complete a questionnaire about dry mouth symptoms.
- Four weeks after the first treatment, participants will have a second treatment for each parotid gland, with the same tests and questionnaires as before.
- Participants will have additional evaluation visits 6 and 8 weeks after the first treatment visit, with a followup telephone call approximately 6 weeks after the last dexamethasone treatment visit.
|Condition or disease||Intervention/treatment||Phase|
|Sj(SqrRoot)(Delta)Gren s Syndrome Xerostomia||Drug: Dexamethasone||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized Within-Subject, Double-Blind, Placebo-Controlled Study of Dexamethasone Irrigation of the Parotid Glands in Primary Sj(SqrRoot)(Delta)Gren's Syndrome Subjects|
|Study Start Date :||May 1, 2011|
|Actual Primary Completion Date :||April 17, 2017|
|Actual Study Completion Date :||April 17, 2017|
- Change in salivary flow from Day 0 to Day 56. [ Time Frame: 56 Days ]
- Change in focus score on biopsy. [ Time Frame: 56 days ]
- Change in salivary flow from Day 0 to study Days 14, 28, 42 and 56. [ Time Frame: 56 days ]
- Change in responses on Patient Dry Mouth Questionnaire. [ Time Frame: 56 days ]
- Change in other assessments of salivary function. [ Time Frame: 56 days ]
- Change in laboratory measures of inflammation. [ Time Frame: 56 days ]
- Change in frequency of AEs. [ Time Frame: 56 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01316770
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Ilias G Alevizos, D.M.D.||National Institute of Dental and Craniofacial Research (NIDCR)|